It's no big deal only in the sense that the market valued this as no deal at all. With US$51 mil SB does not have the funding.
ANP has funding only to do deals, nothing more. Apart from that the company has neither the will nor leadership to go it alone.
The company may want to give 1103 away just to get it back in the clinic and compete with SB and hope for royalties later. Assuming 1103 data remains compelling then sort out the FDA issues and find a partner - that is all ANP can do.
Could Diamond really have been totally blindsided by this?
In relation to the ATL1103 program, page-26
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
